Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986278 in Idiopathic Pulmonary Fibrosis
NCT06003426Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 33
01
Overview
A Phase 3 trial of admilparant in idiopathic pulmonary fibrosis (IPF), sponsored by Bristol Myers Squibb. Started Sep 2023; status: active, not recruiting.
02
Drugs
admilparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06003426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06003426.